BioInvent Announces Positive Efficacy Data in CTCL Cohort of Patients with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
Current TAP Partner
Lund, Sweden – September 9, 2024 – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced additional positive preliminary efficacy data from its ongoing Phase 2a dose expansion study of BI-1808 as a single agent in the CTCL cohort of patients.
- Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) have been observed in the single agent part of the Phase 2a study. Three other patients in the cohort were considered non-evaluable.
- All patients had progressed after standard therapy. The three responding patients had received 9, 3 and 3 previous lines of treatment respectively, and one of them included previous anti-PD1 treatment.
- BI-1808 continues to be impressively safe and well tolerated.